TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37496298

Group type: EXPERIMENTAL
Intervention: parsaclisib 20 mg once daily for 8 weeks, followed by 20 mg once weekly thereafter, in combination with obinutuzumab and bendamustine
Number of subjects: 26
Study: 37496366

Group type: EXPERIMENTAL
Intervention: Tisotumab vedotin (TV)
Number of subjects: 0
Study: 37496394

Group type: EXPERIMENTAL
Intervention: In-person grocery shopping
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Shopping online
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Shopping online with 'default' carts
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Diabetes-friendly recipes via email
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Default cart items acceptance
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Overall intervention
Number of subjects: 65
Study: 37496411

Group type: EXPERIMENTAL
Intervention: Intravenous injection of autologous bone marrow-derived mesenchymal stem cells (BM-MSCs)
Number of subjects: 13
Study: 37496452

Group type: EXPERIMENTAL
Intervention: Intranasal nalmefene (2.7 mg in 0.1 mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular nalmefene (1 mg)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intranasal nalmefene (1 spray in each nostril and 2 sprays in the same nostril)
Number of subjects: 0
Study: 37496612

Group type: EXPERIMENTAL
Intervention: Adintrevimab (300 mg intramuscular injection)
Number of subjects: 2582

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2582
Study: 37497167

Group type: EXPERIMENTAL
Intervention: Parenteral treprostinil initiated at 2 ng/kg/min intravenously or subcutaneously, with up-titration determined by clinicians
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rapid cross-titration in an inpatient setting (median: 2 days)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gradual cross-titration in an outpatient setting (median: 5 days)
Number of subjects: 0
Study: 37497337

Group type: EXPERIMENTAL
Intervention: IRS-High (IRS-H)
Number of subjects: 352

Group type: COMPARATOR
Intervention: IRS-Low (IRS-L)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: IRS-Ultra-Low (IRS-UL) with chemotherapy
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: IRS-H with anti-PD-(L)1
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: IRS
Number of subjects: 352
Study: 37497354

Group type: EXPERIMENTAL
Intervention: Family-based cognitive behavioral therapy (FCBT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Family-based psychoeducation and relaxation training (FPRT)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: FCBT
Number of subjects: 128

Group type: COMPARATOR
Intervention: FPRT
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: FCBT and FPRT
Number of subjects: 128
Study: 37497372

Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS) over the primary motor cortex (M1), 10 daily sessions of 20 minutes each.
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham stimulation (control group).
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: High-definition transcranial direct current stimulation (HD-tDCS) over the primary motor cortex (M1) in higher-frequency migraine patients.
Number of subjects: 25
Study: 37497398

Group type: EXPERIMENTAL
Intervention: Statins use (6.7% reported use, 2346 individuals)
Number of subjects: 35103

Group type: EXPERIMENTAL
Intervention: High dose statins use (0.6% reported use, 212 individuals)
Number of subjects: 35103

Group type: EXPERIMENTAL
Intervention: Age over 60 years
Number of subjects: 35103

Group type: EXPERIMENTAL
Intervention: Living in the Southern region
Number of subjects: 35103

Group type: EXPERIMENTAL
Intervention: Previous diagnosis of myocardial infarction
Number of subjects: 35103

Group type: EXPERIMENTAL
Intervention: Heart failure
Number of subjects: 35103

Group type: EXPERIMENTAL
Intervention: Diabetes
Number of subjects: 35103

Group type: EXPERIMENTAL
Intervention: Dyslipidaemia
Number of subjects: 35103

Group type: EXPERIMENTAL
Intervention: Chronic kidney disease
Number of subjects: 35103

Group type: EXPERIMENTAL
Intervention: Use of anti-hypertensives
Number of subjects: 35103
Study: 37497636

Group type: EXPERIMENTAL
Intervention: End-ischemic dual HOPE for at least 2 hours
Number of subjects: 104

Group type: COMPARATOR
Intervention: Static cold storage (SCS)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: End-ischemic dual HOPE for at least 2 hours (in case of donor risk index >1.70)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Static cold storage (SCS) (in case of donor risk index >1.70)
Number of subjects: 104
Study: 37497674

Group type: EXPERIMENTAL
Intervention: Direct ischemic postconditioning (IPostC) with 4 cycles of 5-minute ischemia followed by 5-minute reperfusion
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Direct ischemic postconditioning (IPostC) in dogs
Number of subjects: 18
Study: 37497675

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation for at least 24 hours
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Time between stroke diagnosis and initiation of mechanical ventilation >1 day
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Various ICU admission variables
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Persistent physical and psychological problems at 1 year
Number of subjects: 364
Study: 37497816

Group type: EXPERIMENTAL
Intervention: Endovenous ablation and compression
Number of subjects: 506

Group type: COMPARATOR
Intervention: Compression therapy alone
Number of subjects: 506

Group type: COMPARATOR
Intervention: Compression with deferred endovenous treatment
Number of subjects: 506
Study: 37497888

Group type: EXPERIMENTAL
Intervention: SLN124 (1.0, 3.0, and 4.5 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: SLN124
Number of subjects: 24
Study: 37497921

Group type: EXPERIMENTAL
Intervention: Combination chemoimmunotherapy and targeted treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional therapies (chemoimmunotherapy or targeted combinations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CLL Treatment-Infection Model (machine learning-based algorithm)
Number of subjects: 0
Study: 37498105

Group type: EXPERIMENTAL
Intervention: 1000 mg of silkworm pupae extract (SWP) per day plus regular exercise (n=27)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo plus regular exercise (n=27)
Number of subjects: 54
Study: 37498255

Group type: EXPERIMENTAL
Intervention: CMR (Cardiac Magnetic Resonance) imaging
Number of subjects: 0
Study: 37498313

Group type: EXPERIMENTAL
Intervention: Modified Reverse Second Dorsal Metacarpal Artery Flap (MRSDMAF)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Modified Cross-Finger Flap (MCFF)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Donor site of MRSDMAF
Number of subjects: 31
Study: 37498369

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation (3 × 10^9 CFU of Lactobacillus and Bifidobacterium species)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 37498415

Group type: EXPERIMENTAL
Intervention: Written emotional disclosure
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Resilience training
Number of subjects: 87

Group type: COMPARATOR
Intervention: Control (no active intervention)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: All arms
Number of subjects: 87
Study: 37498442

Group type: EXPERIMENTAL
Intervention: Open lung extubation strategy
Number of subjects: 69

Group type: COMPARATOR
Intervention: Conventional extubation strategy
Number of subjects: 69
Study: 37498457

Group type: EXPERIMENTAL
Intervention: Transnasal temperature-modulating device (tnTMD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Surface cooling temperature-modulating devices (sTMDs)
Number of subjects: 40
Study: 37498488

Group type: EXPERIMENTAL
Intervention: IV posaconazole
Number of subjects: 10
Study: 37498596

Group type: EXPERIMENTAL
Intervention: Fosaprepitant weekly
Number of subjects: 100

Group type: COMPARATOR
Intervention: Fosaprepitant every 3 weeks
Number of subjects: 100
Study: 37498603

Group type: EXPERIMENTAL
Intervention: 20-week exercise program (3 to 5 sessions/week, 90 min/session) of aerobic plus resistance training
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: 20-week exercise program
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (wait-list control)
Number of subjects: 92
Study: 37498650

Group type: EXPERIMENTAL
Intervention: Asynchronous movement-to-music (M2M) program
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: M2M Live (switch) or individualized behavioral coaching (augmented with the asynchronous M2M program)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Qualitative evaluation through semistructured interviews
Number of subjects: 30
Study: 37498661

Group type: EXPERIMENTAL
Intervention: Online Public Health Nurse-Delivered Group Cognitive Behavioral Therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37498669

Group type: EXPERIMENTAL
Intervention: Parent Positive
Number of subjects: 646

Group type: COMPARATOR
Intervention: FAU
Number of subjects: 646
Study: 37498716

Group type: EXPERIMENTAL
Intervention: Fear of Diabetes Complications Questionnaire (FDCQ)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FDCQ cutoff score for elevated FDC set at ≥30 in the 15-item FDCQ
Number of subjects: 0
Study: 37498821

Group type: EXPERIMENTAL
Intervention: Standard of care plus up to 16 sessions of physical therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 0
Study: 37498909

Group type: EXPERIMENTAL
Intervention: GIR score≤3 (initial functional disability)
Number of subjects: 97
Study: 37499521

Group type: EXPERIMENTAL
Intervention: Binimetinib plus erlotinib (erlotinib 100 mg daily and binimetinib 15 mg BID × 5 days/week)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Binimetinib plus erlotinib
Number of subjects: 43
Study: 37499670

Group type: EXPERIMENTAL
Intervention: Camrelizumab 200 mg intravenously every 2 weeks plus rivoceranib 250 mg orally once daily
Number of subjects: 543

Group type: COMPARATOR
Intervention: Sorafenib 400 mg orally twice daily
Number of subjects: 543

Group type: EXPERIMENTAL
Intervention: Camrelizumab plus rivoceranib
Number of subjects: 543

Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 543
Study: 37499679

Group type: EXPERIMENTAL
Intervention: Pfs230D1-EPA/Alhydrogel (40 μg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pfs25-EPA/Alhydrogel (47 μg)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Pfs25-EPA/Alhydrogel (47 μg) plus Pfs230D1-EPA/Alhydrogel (40 μg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Comparator (Twinrix or Menactra)
Number of subjects: 200
Study: 37499853

Group type: EXPERIMENTAL
Intervention: Multisensory training with the anchor system
Number of subjects: 80

Group type: COMPARATOR
Intervention: Multisensory training without the anchor system
Number of subjects: 80
Study: 37499870

Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Number of subjects: 0
Study: 37499991

Group type: EXPERIMENTAL
Intervention: Moderate pushing
Number of subjects: 1618

Group type: COMPARATOR
Intervention: Intensive pushing
Number of subjects: 1618
Study: 37500008

Group type: EXPERIMENTAL
Intervention: Group-based mindful physical activity (yoga) intervention
Number of subjects: 200

Group type: COMPARATOR
Intervention: Prenatal education control group
Number of subjects: 200
Study: 37500072

Group type: EXPERIMENTAL
Intervention: Endoscopic submucosal dissection (ESD)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Full-thickness resection device (FTRD)
Number of subjects: 275
Study: 37500120

Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound (POCUS)
Number of subjects: 34
Study: 37500236

Group type: EXPERIMENTAL
Intervention: School-based caries prevention program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontreatment years (comparator schools)
Number of subjects: 0
Study: 37500273

Group type: EXPERIMENTAL
Intervention: Carrageenan mouthwash gargle, used morning and night, and around sexual activities for 6 months.
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo mouthwash gargle, used morning and night, and around sexual activities for 6 months.
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Carrageenan mouthwash gargle
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo mouthwash gargle
Number of subjects: 40
Study: 37500274

Group type: EXPERIMENTAL
Intervention: Prehabilitation programme (12-week home-based, tailored programme consisting of physical and/or nutritional and/or psychosocial interventions)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Prehabilitation programme (12-week home-based, tailored programme)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 128
Study: 37500277

Group type: EXPERIMENTAL
Intervention: Non-invasive preimplantation genetic testing for aneuploidy (niPGT-A) and morphology
Number of subjects: 500

Group type: COMPARATOR
Intervention: Morphology alone
Number of subjects: 500
Study: 37500339

Group type: EXPERIMENTAL
Intervention: Atezolizumab (1200 mg every 3 weeks)
Number of subjects: 581

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Atezolizumab
Number of subjects: 581
Study: 37500612

Group type: EXPERIMENTAL
Intervention: 3-weeks induction insulin therapy (glargine/lispro) followed by metformin maintenance with intermittent 2-week courses of insulin every 3-months for 2-years
Number of subjects: 99

Group type: COMPARATOR
Intervention: 3-weeks induction insulin therapy (glargine/lispro) followed by metformin maintenance
Number of subjects: 99
Study: 37500647

Group type: EXPERIMENTAL
Intervention: Nivolumab + Interferon-gamma (IFN-γ)
Number of subjects: 26
Study: 37500714

Group type: EXPERIMENTAL
Intervention: In vivo magnetic resonance spectroscopy (MRS) technique utilizing frequency-selective editing pulses
Number of subjects: 0
Study: 37500926

Group type: EXPERIMENTAL
Intervention: Reirradiation (specifically hyperfractionated radiotherapy) for recurrent, inoperable nasopharynx cancer
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Reirradiation for glioma
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care for recurrent disease after previous radiotherapy
Number of subjects: 60
Study: 37500930

Group type: EXPERIMENTAL
Intervention: Smartphone application targeting physical activity for 12 weeks
Number of subjects: 146

Group type: COMPARATOR
Intervention: Control group (no smartphone application)
Number of subjects: 146
Study: 37500950

Group type: EXPERIMENTAL
Intervention: Prime Time Sister Circles® intervention (peer-based support group, 2 hours/week for 13 weeks)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 172
Study: 37501016

Group type: EXPERIMENTAL
Intervention: gavo-cel (T cell receptor fusion construct) administered as a single agent (n=3) or after lymphodepletion (n=29)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: gavo-cel (T cell receptor fusion construct)
Number of subjects: 32
Study: 37501020

Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI)
Number of subjects: 192
Study: 37501059

Group type: EXPERIMENTAL
Intervention: Hyperhomocysteinemia (HHcy)
Number of subjects: 11189

Group type: EXPERIMENTAL
Intervention: Higher serum level of total Hcy
Number of subjects: 11189
Study: 37501063

Group type: EXPERIMENTAL
Intervention: 22510SS intervention (2 hours of outdoor activities, limit screen time to 2 hours, consume 5 servings of fruits and vegetables, 1 hour of physical activity, no sugar-sweetened beverages, reasonable sleep duration, regular supervision)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 37501078

Group type: EXPERIMENTAL
Intervention: Meaningful Roles program
Number of subjects: 0
Study: 37501102

Group type: COMPARATOR
Intervention: Information only (community health workers provide basic information on high blood pressure and salt consumption)
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Free low-sodium salt substitute (LSSS) with education on benefits
Number of subjects: 309
Study: 37501172

Group type: EXPERIMENTAL
Intervention: Breathe Melodies for Mums (M4M) online singing intervention, 6-week duration.
Number of subjects: 37
Study: 37501180

Group type: EXPERIMENTAL
Intervention: Low-threshold HCV treatment model at a syringe services program
Number of subjects: 29
Study: 37501206

Group type: EXPERIMENTAL
Intervention: Vegetarians
Number of subjects: 413914

Group type: COMPARATOR
Intervention: Occasional meat-eaters
Number of subjects: 413914

Group type: COMPARATOR
Intervention: Pescatarians
Number of subjects: 413914

Group type: COMPARATOR
Intervention: Regular meat-eaters
Number of subjects: 413914
Study: 37501212

Group type: EXPERIMENTAL
Intervention: VLED (640 kcal/day) during 12 or 16 weeks, depending on baseline BMI < 40 or ≥ 40 kg/m²
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37501217

Group type: EXPERIMENTAL
Intervention: Dynamic hand orthosis with task-oriented upper limb training for 12 weeks (3 weeks supervised, 9 weeks unsupervised)
Number of subjects: 15
Study: 37501509

Group type: EXPERIMENTAL
Intervention: SURGICEL® Powder (SURGICEL®-P)
Number of subjects: 103
Study: 37501632

Group type: EXPERIMENTAL
Intervention: Family caregiver interactions with nursing home staff
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Staff management of resident behavioral symptoms
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Nursing home context
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Family caregiver knowledge of dementia
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Family caregiver strain
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Resident experience
Number of subjects: 30
Study: 37502272

Group type: EXPERIMENTAL
Intervention: Bootle Blast videogame intervention for upper limb functional exercise, played at home for 12 weeks.
Number of subjects: 4
Study: 37502338

Group type: EXPERIMENTAL
Intervention: Fecal immunochemical test (FIT)
Number of subjects: 9989

Group type: EXPERIMENTAL
Intervention: Multitarget stool DNA test (mt-sDNA)
Number of subjects: 9989

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 9989
Study: 37502424

Group type: EXPERIMENTAL
Intervention: Human probiotics and prebiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37502440

Group type: EXPERIMENTAL
Intervention: Serum UCA1
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Serum WRAP53
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of UCA1, WRAP53, and serum α-fetoprotein (AFP)
Number of subjects: 90
Study: 37502622

Group type: EXPERIMENTAL
Intervention: AK0529 2 mg/kg bid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AK0529
Number of subjects: 0
Study: 37502721

Group type: EXPERIMENTAL
Intervention: Very low-calorie ketogenic diet (VLCKD)
Number of subjects: 20
Study: 37503002

Group type: EXPERIMENTAL
Intervention: Abbott Freestyle Libre Pro
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Dexcom G4 Platinum
Number of subjects: 30

Group type: COMPARATOR
Intervention: Duplicate meals
Number of subjects: 30
Study: 37503152

Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Endotracheal Tube (ETT)
Number of subjects: 67
Study: 37503157

Group type: EXPERIMENTAL
Intervention: Blood biomarker panel (kidney injury molecule-1, N-terminal pro-B-type natriuretic peptide, osteopontin, and tissue inhibitor of metalloproteinase-1)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Blood biomarker panel
Number of subjects: 241
Study: 37503357

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) with a single fraction of 25 Gy
Number of subjects: 5
Study: 37503561

Group type: EXPERIMENTAL
Intervention: Anti-RBD IgG concentrations ≥1000 BAU/mL
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Anti-RBD IgG concentrations ≥3000 BAU/mL
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Hybrid immunity group
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: IFN-γ release post-SARS-CoV-2 peptide stimulation
Number of subjects: 636
Study: 37503575

Group type: EXPERIMENTAL
Intervention: Mastic mouthwash
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 30
Study: 37503602

Group type: EXPERIMENTAL
Intervention: >20% reduction in NT-proBNP levels
Number of subjects: 3821

Group type: EXPERIMENTAL
Intervention: >20% rise in NT-proBNP levels
Number of subjects: 3821

Group type: EXPERIMENTAL
Intervention: ≤20% change in NT-proBNP levels
Number of subjects: 3821
Study: 37503629

Group type: EXPERIMENTAL
Intervention: Men with layered plaques
Number of subjects: 533

Group type: EXPERIMENTAL
Intervention: Women with layered plaques
Number of subjects: 533

Group type: COMPARATOR
Intervention: Layered plaques in men
Number of subjects: 533

Group type: COMPARATOR
Intervention: Layered plaques in women
Number of subjects: 533
Study: 37503661

Group type: EXPERIMENTAL
Intervention: Encoberminogene rezmadenovec (XC001) administered via epicardial delivery
Number of subjects: 12
Study: 37504371

Group type: EXPERIMENTAL
Intervention: High level of alkaline phosphatase (AP)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Poor chemotherapy-induced tumor necrosis
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Presence of metastases at presentation
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Serum levels of erythrocyte sedimentation rate (ESR)
Number of subjects: 210
Study: 37504555

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) for breast cancer
Number of subjects: 101
Study: 37505106

Group type: EXPERIMENTAL
Intervention: SyMRI-based radiomic features at midtreatment
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Multivariable radiomics models of maps acquired at midtreatment
Number of subjects: 181
Study: 37505107

Group type: EXPERIMENTAL
Intervention: High-standard group (FTV0 model)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Standard group (FTV0 model)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: High-standard group (∆FTV1 model)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Standard group (∆FTV1 model)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: High-standard group (∆FTV2 model)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Standard group (∆FTV2 model)
Number of subjects: 432

Group type: EXPERIMENTAL
Intervention: High-standard group (multiple predictor model)
Number of subjects: 432

Group type: COMPARATOR
Intervention: Standard group (multiple predictor model)
Number of subjects: 432